BridgeBio Pharma
1D
1W
1M
3M
YTD
1Y
5Y
ALL
Why Robinhood?
Robinhood gives you the tools you need to put your money in motion. You can buy or sell BBIO and other ETFs, options, and stocks.About BBIO
BridgeBio Pharma, Inc. engages in identifying and advancing transformative medicines to treat patients who suffer from Mendelian diseases. Its pipeline of development programs includes product candidates ranging from early discovery to late-stage development.
CEONeil Kumar
CEONeil Kumar
Employees730
Employees730
HeadquartersPalo Alto, California
HeadquartersPalo Alto, California
Founded2015
Founded2015
Employees730
Employees730
BBIO Key Statistics
Market cap8.83B
Market cap8.83B
Price-Earnings ratio-13.24
Price-Earnings ratio-13.24
Dividend yield—
Dividend yield—
Average volume2.64M
Average volume2.64M
High today$47.36
High today$47.36
Low today$46.14
Low today$46.14
Open price$47.05
Open price$47.05
Volume2.07M
Volume2.07M
52 Week high$48.68
52 Week high$48.68
52 Week low$21.72
52 Week low$21.72
BBIO News
TipRanks 5d
BridgeBio Pharma’s Growth Potential Highlighted by Positive Outlook on BBP-418 and FDA SupportBank of America Securities analyst Jason Zemansky has maintained their bullish stance on BBIO stock, giving a Buy rating today. Elevate Your Investing Strategy...
TipRanks 5d
BridgeBio Pharma’s BBP-418: A Promising Investment in Groundbreaking LGMD2I/R9 TherapyTiago Fauth, an analyst from Wells Fargo, maintained the Buy rating on BridgeBio Pharma. The associated price target remains the same with $76.00. Elevate Your...
Analyst ratings
90%
of 21 ratingsBuy
90.5%
Hold
9.5%
Sell
0%
People also own
Based on the portfolios of people who own BBIO. This list is generated using Robinhood data, and it’s not a recommendation.